You are here

Effective New Topical Treatment to Reduce Scar Formation in Burns

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W81XWH-13-C-0053
Agency Tracking Number: H122-016-0254
Amount: $149,904.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: DHP12-016
Solicitation Number: 2012.2
Solicitation Year: 2012
Award Year: 2013
Award Start Date (Proposal Award Date): 2013-05-30
Award End Date (Contract End Date): 2013-12-31
Small Business Information
1420 N. Claremont Blvd Suite 105D
Claremont, CA -
United States
DUNS: 830276353
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Shenda Baker
 (909) 447-6858
Business Contact
 Christopher Ryan
Title: Associate Director
Phone: (909) 447-6858
Research Institution

Thermal injury is common in military conflicts due to primarily to the widespread use of explosive devices. Burns can produce scars that are excessive, physically debilitating and functionally damaging. There is a critical need for an effective product that can control bacterial contamination and prevent colonization, mitigate inflammation, and diffuse to or reach necrotic and damaged tissue resulting from a blast or traumatic thermal wound to reduce the formation of fibrotic scars. Synedgen has developed a biocompatible polysaccharide derivative (PAAG) that has been demonstrated in vivo and in vitro to reduce inflammation and provide enhanced healing with the reduction of scarring. This Phase 1 study will demonstrate the extent to which PAAG mitigates scar reduction in full thickness burns in a porcine model, and provide an opportunity to examine innate immune responses, inflammatory cytokines and healing pathways.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government